Valuation
26% of the score
25median 13
Neurocrine Biosciences, Inc. is valued at 20.8x its operating profit, including debt: a rich multiple.
25x
20x
15x
10x
6x
20.8x
Full points at 6x or less, none from 25xfull points
NBIXNeurocrine Biosciences, Inc.
$140.45-2.3% 1Y
$140.45
$123.1052 weeks$182.85
RyuScore
Seven criteria, each scored 0 to 100 on a published scale, weighted into one number.
RyuScore 62 out of 100, Above average
Above average. Neurocrine Biosciences, Inc. scores higher than 71% of the 1,794 companies Ryufin scores.
Carried by return on new capital and return on capital, held back by valuation and cycle position.
Healthcare median 27 · all companies 50
Return on capital
18% of the score
88median 34
Over 7 years the business earned 19% a year after tax on the capital it uses.
2%
8%
15%
25%
19%
None at 2% or less, full points from 25%full points
7 years agolatest 18%
Return on new capital
16% of the score
100median 49
For every dollar of operating profit earned over 6 years, yearly profit grew by 22 cents. New capital earned 21%, and 105% of profit went back into the business.
-5%
12%
22%
None at minus 5 cents, full points from 12 centsfull points
Capital allocation
14% of the score
66median 64
How management spends the money: shares bought back or issued, and whether assets grow faster than the business they serve.
Share countUp 0.9% a year over 5 years: new shares
515%
-3%
0.9%
0 pointsfull points
Assets against salesAssets grew 22% a year, sales 22%
9012%
-2%
-0.6%
0 pointsfull points
Cycle position
12% of the score
10median 62
Today's operating margin of 24% is 1.79x its normal 13%: near a peak, where margins tend to fall back. Normal is half the 10 year median, half the last four years, so a margin that has held is not taken for a peak.
2x
1.5x
1x
0.7x
1.8x
A trough earns points, a peak costs themfull points
10 years agonow 24%
Balance sheet
8% of the score
100median 50
What the debt weighs against the profit that has to carry it.
Interest coverOperating profit covers interest 173x
1001.5x
12x
172.8x
0 pointsfull points
Earnings quality
6% of the score
91median 90
Whether the reported profit arrives as cash, and whether the accounts show the usual signs of stretching.
Cash against profitOperating cash flow was 1.65x profit over 3 years
1000.7x
1x
1.3x
1.7x
0 pointsfull points
AccrualsCash ran ahead of profit by 7.3% of assets
968%
0%
-8%
-7.3%
0 pointsfull points
Beneish M-score-2.54
76-1.50
-1.78
-2.22
-3.00
-2.54
0 pointsfull points
How the RyuScore works
Each criterion earns 0 to 100 points on the scale drawn under it, and the RyuScore is their average weighted 26, 18, 16, 14, 12, 8 and 6. Scales bend in the company's favour between their ends, so an ordinary figure is never already near zero. Where a criterion cannot be measured from the filings it is taken out and the remaining weights scale up; a company needs 60% of the weight covered, and always a price, to get a score.
Built from the company's annual and quarterly filings with the SEC and today's share price. Banks, insurers and property trusts are not scored: their debt is their raw material, so these yardsticks mean something else there. Figures as of 2026-06-30, latest annual report FY2025.
On our screens:Cheap stocks by free cash flow yield
Drug Manufacturers, Specialty & Generic
Ranks #8 of 29 by RyuScore